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Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder that causes progressive memory and cognitive
decline during middle to late adult life. The AD brain is characterized by deposition of amyloid b peptide (Ab), which is
produced from amyloid precursor protein by b- and c-secretase (presenilin complex)-mediated sequential cleavage.
Induced pluripotent stem (iPS) cells potentially provide an opportunity to generate a human cell-based model of AD that
would be crucial for drug discovery as well as for investigating mechanisms of the disease.
Methodology/Principal Findings: We differentiated human iPS (hiPS) cells into neuronal cells expressing the forebrain
marker, Foxg1, and the neocortical markers, Cux1, Satb2, Ctip2, and Tbr1. The iPS cell-derived neuronal cells also expressed
amyloid precursor protein, b-secretase, and c-secretase components, and were capable of secreting Ab into the conditioned
media. Ab production was inhibited by b-secretase inhibitor, c-secretase inhibitor (GSI), and an NSAID; however, there were
different susceptibilities to all three drugs between early and late differentiation stages. At the early differentiation stage,
GSI treatment caused a fast increase at lower dose (Ab surge) and drastic decline of Ab production.
Conclusions/Significance: These results indicate that the hiPS cell-derived neuronal cells express functional b- and c-
secretases involved in Ab production; however, anti-Ab drug screening using these hiPS cell-derived neuronal cells requires
sufficient neuronal differentiation.
Citation: Yahata N, Asai M, Kitaoka S, Takahashi K, Asaka I, et al. (2011) Anti-Ab Drug Screening Platform Using Human iPS Cell-Derived Neurons for the Treatment
of Alzheimer’s Disease. PLoS ONE 6(9): e25788. doi:10.1371/journal.pone.0025788
Editor: Hitoshi Okazawa, Tokyo Medical and Dental University, Japan
Received May 26, 2011; Accepted September 10, 2011; Published September 30, 2011
Copyright:  2011 Yahata et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by Core Research for Evolutional Science and Technology, Japan Science and Technology Agency (HI & NI), and a research
grant from the NOVARTIS Foundation for Gerontological Research (HI). The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: haruhisa@cira.kyoto-u.ac.jp (HI); iwata-n@nagasaki-u.ac.jp (NI)
Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
in the elderly. It is characterized clinically by progressive declines
in memory, executive function, and cognition. It is also
characterized by pathological features, including the deposition
of amyloid plaques and neurofibrillary tangles as well as neuronal
and synaptic loss in particular areas of the brain [1]. Accumulation
of amyloid b peptide (Ab) is hypothesized to initiate the pathogenic
cascade that eventually leads to AD. The amyloid hypothesis is
based on an imbalance between the production and clearance of
Ab [2]. Ab is produced by b- and c-secretase-mediated sequential
proteolysis of amyloid precursor protein (APP) and plays a central
role in AD pathogenesis. Because b- and c-secretases are directly
involved in Ab production, they are straightforward and attractive
therapeutic targets for AD. A number of compounds that inhibit
or modulate these secretase activities and Ab levels in vitro and in
vivo have to date been developed [3,4].
Development of a human, cell-based in vitro assay system is a
basic requisite for drug discovery and for investigating mechanisms
of the disease. Induced pluripotent stem (iPS) cells reprogrammed
from somatic cells [5,6] provide an opportunity to easily generate
and use patient-specific differentiated cells. Because previous AD
assay systems using human cancer cell lines or primary rodent cell
cultures did not perfectly present the human intracellular
environment or components, human iPS (hiPS) cell-derived
neuronal cells may enable the development of more efficient
drugs, such as c-secretase modulators, and the better elucidation of
AD mechanisms. In this study, we successfully generated forebrain
neurons from hiPS cells, and showed that Ab production in
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secretase inhibitors and modulators. Thus, we provide a new
platform for AD drug development, which might be applied to AD
patient-specific iPS cell research.
Results
Differentiation of forebrain neurons from hiPS cells
Recently, forebrain neurons were successfully differentiated
from mouse embryonic stem (ES) cells [7,8,9] and human ES and/
or iPS cells [9,10,11]. The methods used for differentiation into
spinal motor neurons and midbrain dopaminergic neurons
required the morphogens retinoic acid (RA)/sonic hedgehog
(SHH) and fibroblast growth factor 8 (FGF8)/SHH, respectively
[11,12]. On the other hand, non-morphogens [10,11] or Lefty A
and Dickkopf homolog 1 (Dkk1) [7,9] have been used for the
induction of hiPS cells into forebrain neurons. Because amyloid
plaques are observed in the cerebral cortex from the early stage of
AD development [13], stem cells should be differentiated to at
least forebrain neurons for in vitro assays in AD research.
We differentiated forebrain neurons from hiPS 253G4 cells,
which were generated from human dermal fibroblasts using three
reprogramming factors (Oct3/4, Sox2, and Klf4) [14], as
described previously (Figure 1A) [12,15]. When neural stem cells
were induced with Noggin and SB431542 for 17 days, we obtained
cells that were positive for the neuroectodermal marker, Nestin
(Figure 1B), as previously reported using human and monkey ES
cells [15]. After culturing the cells with morphogen-free medium
for days 17–24, Forkhead box G1 (Foxg1) expression was induced
and Foxg1-positive cells were observed (Figure 1C, D) [11,15]. We
also examined whether treatment with cyclopamine, an SHH
inhibitor, increased the number of neurons presenting a
glutamatergic phenotype as observed in mouse ES cells [8]. The
expression level of vesicular glutamate transporter 1 (vGlut1), a
glutamatergic marker, was not significantly increased by the
addition of cyclopamine (final concentration 1 mM) from days 17
to 24 (data not shown). Therefore, we did not add cyclopamine in
this period in subsequent experiments. At day 24, dissociated cells
were reseeded on 24-well plates to further characterize the cells.
Next, we evaluated the hiPS cell-derived neuronal cells using
four cortical layer-specific markers, T-brain-1 (Tbr1) and chicken
ovalbumin upstream promoter transcription factor (COUP-TF)-
interacting protein 2 (Ctip2) [9,10,11], and cut-like homeobox 1
(Cux1) and special AT-rich sequence-binding protein 2 (Satb2)
[16]. Quantitative polymerase chain reaction (qPCR) revealed that
expression levels of these markers were increased in a differenti-
ation day-dependent manner (Figure 1E). At day 52, all four of
these markers were visualized by immunocytochemistry (ICC)
(Figure 1F). The percentages of marker-positive cells relative to the
total number of cells were 62.262.9% for Tbr1, 11.963.0% for
Ctip2, 82.665.0% for Cux1, and46.067.1% for Satb2. The
population of each marker-positive cell was similar to that of data
reported previously in human fetal brain around gestational week-
20 [16]. In this experimental schedule, most cells expressed one or
a few neocortical markers at day 52.
Characterization of hiPS cell-derived neuronal cells
Cells that were reseeded at day 24, were sparsely adhered to the
culture plate and had proliferated and extended neurites in a time
course-dependent manner as observed by the neuronal marker,
class-III b-tubulin (Tuj1), and microtubule-associated protein 2
(MAP2) (Figure 2A). Tuj1 expression was almost saturated at day
45 (Figure 2B), but MAP2 and synapsin I expression were still
increasing (Figure 2C, D). Synaptic development continued until
day 52, and many synapsin I-positive puncta were detected by
ICC at day 52 (Figure 2A). Expression of the glial marker, glial
fibrillary acidic protein (GFAP), was highest at day 52 in this
schedule (Figure 2E). This sequential expression pattern is similar
to that reported recently in human pluripotent stem cell-derived
neurons; the synapsin I-positive neuronal and GFAP-positive glial
cultures at day 52 corresponded to the stage at which spontaneous
neuronal activity was observed [17].
We then examined the neurotransmitter phenotypes of these
differentiated neurons by evaluating the synthesizing enzymes for
two typical cortical neurotransmitters, glutamate and c-aminobu-
tyric acid (GABA). Expression of the glutamatergic neuronal
marker, phosphate-activated glutaminase (PAG) [18], and the
GABAergic neuronal marker, glutamate decarboxylase (GAD),
were observed by ICC at day 52 (Figure 2F). PAG- and GAD-
positive neurons comprised 60620% and 564% of total cells,
respectively. Most of the Tuj1-positive neurons were also co-
localized with the punctate signals of vGlut1 (Figure 2G). GABA-
positive neurons comprised a similar population to the GAD-
positive ones (Figure 2F, H). On the other hand, cholineacetyl-
transferase (ChAT) or vesicular acetylcholine transporter
(VAChT)-positive cholinergic neurons were little observed at day
52, although their mRNA level increased with differentiation time
(Figure S1). These data showed that a majority of differentiated
neuronal cells possessed a glutamatergic phenotype in the present
condition.
Differentiated neuronal cells express some components
related to Ab production
To evaluate their usefulness as an AD model, we measured the
levels of Ab secreted from the differentiated neuronal cells at days
38, 45, and 52. In the non-amyloidogenic pathway, a-secretase
cleaves full-length APP (FL-APP) within the Ab domain to the
large soluble APP fragment (sAPPa) and APP-C terminal fragment
a (CTFa) (Figure 3) [19]. In the amyloidogenic pathway, b-
secretase, b-site APP cleaving enzyme 1 (BACE1), cleaves APP on
the N-terminal side of the Ab domain to soluble sAPPb and APP-
CTFb (Figure 3). FL-APP and its cleavage products were
increased in a time-course-dependent manner (Figure 3).
APP has three alternatively spliced isoforms: APP695, APP751,
and APP770. APP695 is most abundantly expressed in neurons,
whereas APP751 and APP770 show more ubiquitous expression
patterns [20]. In cell lysates, we detected three separate APP
variants on western blots. The estimated percentages of the
neuron-dominant variant APP695 were 64.561.0%, 68.662.2%,
and 69.662.1% at days 38, 45, and 52, respectively (Figures 3A
and S2). The neuronal population at day 52 was approximately
consistent with the sum of the percentages of the glutamatergic
and GABAergic neurons mentioned above.
The aspartyl protease BACE1, the major b-secretase involved in
cleaving APP, is a significant molecule for AD pathology because
BACE1 protein levels and activity are increased in the brains of
patients with the sporadic form of AD [21]. In our differentiated
neurons, BACE1 protein levels were increased in a time course-
dependent manner (Figure 4A, B), and we speculated that the
upregulation of BACE1 protein levels may be due to a
posttranscriptional mechanism [22]. BACE1 mRNA levels were
slightly elevated with time (Figure 4B). These data may indicate
that increased BACE1 protein levels were mainly induced by
translational activation along with neuronal differentiation.
APP-CTFb is cleaved to Ab and APP intercellular domain
(AICD) by c-secretase (Figure 3). The c-secretase complex consists
of four core members, presenilin (PS; either PS1 or PS2), nicastrin,
Pen-2, and Aph-1 [23]. PS1, nicastrin, and Pen-2 were detected by
Ab Production in hiPS Cell-Derived Neuronal Cells
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25788western blotting, but their expression levels did not change
markedly over time (Figure 4A, C). Aph-1 has two isoforms in
human, Aph-1A and Aph-1B, which are considered to have
different effects on the production of Ab species related to AD
[24]. Their expression levels measured by qPCR were relatively
constant (Figure 4D). The Aph-1B/Aph-1A ratios also did not
show significant differences among the time points analyzed here
(Figure 4E).
Ab has several species, including Ab40 and Ab42, which have
emerged as two of the most robust Ab measurements in brain.
Recent studies suggest that Ab40 and Ab42 may have different
effects on Ab aggregation or oligomerization [25,26]. We
measured Ab40 and Ab42 secreted into conditioned media for 2
days by sandwich ELISA. Both types of Ab increased with time
(Figure 5A). The level of Ab40 was higher than that of Ab42,
compatible with previous reports [4,27,28,29,30]. Interestingly,
the ratio of Ab42/Ab40 was highest at day 38, and there was no
significant difference between days 45 and 52 (Figure 5B).
Inhibition of Ab40 and Ab42 secretion
We examined whether the differentiated neurons contained
funtional b- and c-secretases and whether Ab secretion could be
controlled. We selected the most effective, commercially available
b- and c-secretase inhibitors, b-secretase inhibitor IV (BSI) [31]
Figure 1. Differentiation of forebrain neurons from hiPS cells. (A) Experimental scheme of neural differentiation from hiPS cells, 253G4.
Nestin-positive neuroepithelial cells (B) and Foxg1-positive cells (C) were observed at days 17 and 24, respectively. Scale bar, 50 mm. Expression levels
of Foxg1 (D) and the neocortical markers Tbr1, Ctip2, Cux1, and Satb2 (E) at days 0, 24, and 52. Expression levels were measured by qPCR and
normalized by that of GAPDH. ‘‘Fold expression’’ is shown as a ratio of day 24/day 0 or day52/day 0. Each column represents the mean 6 SD of 3
assays.
*p,0.05,
**p,0.01,
***p,0.001, significantly different from day 0 by Dunnett’s test. (F) ICC staining of Tbr1-, Ctip2-, Cux1- and Satb2-positive
cells at day 52. Scale bar, 50 mm.
doi:10.1371/journal.pone.0025788.g001
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tively. We also examined the effect of a non-steroidal anti-
inflammatory drug (NSAID), sulindac sulfide [33], because some
NSAIDs directly modulate c-secretase activity to selectively lower
Ab42 levels [33,34]. The cells were treated with each drug for 2
days, and Ab was monitored in the collected media at day 38 or
52.
There were different susceptibilities to all three drugs between
days 38 and 52 (Figure 6) as revealed by two-way analysis of
variance (ANOVA) [significant interaction between day and dose
(BSI, p,0.001 in Ab40 and Ab42, respectively; GSI, p,0.001 in
Ab40 and Ab42, respectively; NSAID, p,0.001 in Ab42)].
Following BSI and NSAID treatment, secretion of Ab40 and
Ab42 was decreased in a dose-dependent manner (Figure 6A, B,
E, and F). NSAID especially showed more efficient inhibition of
Ab42 than that of Ab40, consistent with a previous report [33].
Following GSI treatment (Figure 6C, D), secretion of both Ab40
and Ab42 was increased at lower doses (10
211–10
28 M), but was
inhibited at higher doses (10
27–10
26 M) at day 52. This
phenomenon, which is called a ‘‘gradual Ab rise’’, was observed
following the addition of other GSIs in a cell line system [35]. On
the other hand, secretion of both Ab40 and Ab42 at day 38
showed a fast increase at lower doses (10
211–10
29 M) (Ab surge)
and drastic decline at 10
28 M. We also examined the effects of
these inhibitors on cell viability using the lactate dehydrogenase
(LDH) assay. Two-day-treatments with the highest concentrations
Figure 2. Characterization of neuronal and glial cells differentiated from hiPS cells. (A) Time-dependent morphological changes of cells
reseeded in a 24-well plate. Neuronal and glial cells were stained by anti-Tuj1 (left; red), anti-synapsin I (left; green), anti-MAP2 (right; red), and anti-
GFAP (right; green) antibodies and DAPI (right; blue) at 38, 45, and 52 days. Scale bar, left; 20 mm, right; 50 mm. Expression levels of Tuj1 (B), synapsin I
(C), MAP2 (D), and GFAP (E) at days 0, 24, 38, 45, and 52 were measured by qPCR and normalized by that of GAPDH. ‘‘Fold expression’’ is the ratio of
expression at each day compared to day 0. Each point represents mean 6 SD of 3 assays.
*p,0.05,
**p,0.01,
***p,0.001, significantly different from
day 0 by Dunnett’s test. (F–H) Neurotransmitter phenotypes at day 52. PAG (red)- and GAD (green)-positive (F), vGlut1 (green)- and Tuj1 (red)-positive
(G), and GABA (green)- and Tuj1 (red)-positive cells (H). Blue, DAPI. Scale bar, 50 mm.
doi:10.1371/journal.pone.0025788.g002
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also traced these experiments using human ES (hES) cell (H9)-
derived neuronal cells (Figure S4) because remaining expression of
reprogramming factors, Oct3/4 and Klf4, were observed in hiPS
cell (253G4)-derived neuronal cells (Figure S6). The Ab produc-
tion and its inhibition by these drugs in hES cell-derived neuronal
cells were relatively similar to those in hiPS cell-derived ones
(Figure S5). These data showed that BSI, GSI, and NSAID
partially or fully blocked Ab production in the hiPS cell-derived
neuronal cells, indicating that these cells expressed functional b-
and c-secretases.
Discussion
AD is the most common cause of dementia in the elderly, with
progressive neuronal loss in the cerebral cortex and hippocampal
formation. Although the underlying etiology of most AD remains
unclear, Ab is thought to play a pivotal role in its pathogenesis.
Studies from animal and cellular models have shown that
mutations in the APP, PS1, and PS2 genes affected the production
of Ab, which contributes to the formation of amyloid plaques [19].
In several strains of mouse models, Ab levels in brain tissue,
cerebrospinal fluid (CSF), and plasma have been associated with
AD pathogenesis and cognitive impairment [27,28,36]. Human
samples from clinical AD patients have also been used for
pathological and biochemical analyses to understand the etiology
of AD. Ab levels in CSF and plasma have been examined to
evaluate their risks for AD [29,37], but brain tissues are only
available postmortem for such analyses. On the other hand,
immortalized human cell lines derived from kidney or brain,
primary neurons derived from mice and rats, or cells artificially
overexpressing APP or presenilin with or without familial AD
mutations have been utilized for in vitro studies [4,30]. There is no
doubt that these cells are quite different from living neurons in the
human body in terms of innate qualities. Although we have had no
choice until recently, important advances in technology of iPS cells
may now provide the opportunity to use intact human-derived
neuronal cells [38].
We evaluated whether iPS cell-derived neuronal cells could be
applied to an in vitro cell-based assay system for AD research. In
particular, further investigations into the metabolic mechanisms of
Ab are requisite for drug development to treat the brains of
patients afflicted with AD. In this respect, we provide a profile of
the molecular components associated with Ab production in hiPS
cell-derived neuronal cells and propose to add an Ab assay system
using these cells to the panel of generalized Ab-monitoring systems
(Table 1). Human neuronal cells are considered to provide more
accurate human neuronal conditions within which to evaluate
drug efficacy or toxicity than other human cell lines (e.g., cancer
lines). Furthermore, we would be able to investigate how hiPS cell-
derived neuronal cells reflect AD-related physiological and
pathological conditions based on Ab production.
In the present study, we characterized iPS cell-derived neuronal
cells in terms of their expression of neuronal and glial markers by
exposing them to Noggin and SB431542 during their differenti-
ation (Figures 1 and 2). We observed increases in GFAP mRNA
levels and in synapsin I-positive synaptic puncta at day 52. This
was consistent with data showing that the existence of astrocytes
promotes synaptic activity in human ES cell-derived neurons [40].
When differentiation occurred in the presence of non-morpho-
gens, we obtained mainly glutamatergic neurons (Figure 2F, G),
quite in line with previous reports of concerning hES and hiPS
cells [10,11]. Expression of the forebrain marker Foxg1 suggests a
default forebrain identity of the 253G4 iPS cells used in this study
(Figure 1C, D). We also observed the expression of the neocortex-
specific transcriptional factors Tbr1, Ctip2, Cux1, and Satb2
(Figure 1E, F). These expression schemes appear to mimic human
neocortical development in vitro [16], although further analyses are
needed to assist in understanding human neuronal subtype-specific
differentiation.
This is the first study to observe the expression of APP, b- and c-
secretase, and the production of Ab in hiPS cell-derived neuronal
Figure 3. APP was expressed in hiPS cell-derived neuronal cells. HiPS cell-derived neuronal cells express full-length APP, sAPPa, sAPPb, APP-
CTFa, APP-CTFb and AICD at 38, 45, and 52 days. (A) Representative western blots of APP and its fragments. (B) Each column represents mean 6 SD
of 8 samples measured by quantitative western blot analysis and normalized by that of b-actin. ‘‘Fold expression’’ represents the ratio of expression
on the given day compared to day 38.
*p,0.05,
**p,0.01,
***p,0.001, Tukey’s test.
doi:10.1371/journal.pone.0025788.g003
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increased (Figures 3 and 4), but protein levels of c-secretase
components were not significantly different during the period from
day 38 to 52 (Figure 4C, D). Ab production in hiPS cell 253G4-
derived neuronal cells increased with differentiation course
(Figure 5A), however that in another hiPS cell 201B7 [5]- and
in hES H9-derived neuronal cells did not increase (Figures S5 and
S7) although all cell lines showed development of synapse (Figure
S4A) as Ab releasing site [41], indicating that besides synapto-
genesis, subtle changes in localization and assembly of APP [42],
BACE1, c-secretase components would be critical for Ab
production.
The Ab42/Ab40 ratio unexpectedly showed a significant
decrease from day 38 to 45 (Figure 5B). Serneels et al. reported
that the c-secretase complex containing Aph-1B was active and
involved in the generation of amyloidogenic Ab42 [24]. Our data
showed that the Aph-1B/Aph-1A ratio did not change signifi-
cantly with cell differentiation (Figure 4E); therefore, the Ab42/
Ab40 ratio may be influenced by other unknown factors
interacting directly or indirectly with c-secretase.
Figure 4. b-Secretase and c-secretase components were expressed in hiPS cell-derived neuronal cells. The hiPS cell-derived neuronal
cells express BACE1 protein and mRNA (B), c-secretase components; presenilin 1(PS1), nicastrin, Pen-2 (C), and Aph-1A, and Aph-1B (D) at days 38, 45,
and 52. Expression levels were quantified by western blot analysis (n=8) (B, C) or qPCR (n=3) (D) and normalized by that of b-actin. ‘‘Fold expression’’
represents the ratio of expression on the given day compared to day 38. (E) The ratio Aph-1B/Aph-1A. Data represent mean 6 SD. (A) Representative
western blots of BACE1 and c-secretase components at 38, 45, and 52 days.
*p,0.05,
**p,0.01,
***p,0.001, Tukey’s test.
doi:10.1371/journal.pone.0025788.g004
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production in this human neuronal cell system (Figure 6). The
inhibitory effect on Ab production by GSI showed a characteristic
difference between days 38 (Ab surge) and 52 (gradual Ab rise)
(Figure 6C, D). Ab surge at day 38 was also observed in another
hiPS cell (201B7)-derived neuronal cells (Figure S7) as well as in
hES cell line, H9-derived ones (Figure S5). At day 38, GSI might
promote neuronal differentiation with synaptogenesis via blocking
Notch signaling [43] rather than inhibition of Ab production,
leading to Ab surge. Another possible explanation for Ab surge is
that change in conformation or components of the c-secretase
affects the sensitivity of c-secretase to GSI (total Ab,A b40, Ab42,
and Ab42/Ab40), although levels of mRNA and the ration for
Aph-1A and Aph-1B do not change between days 38 and 52
(Figure 4D, E) Thus, for precise Ab monitoring in human stem
cell-derived neuronal cells, it is necessary to use neuronal cells with
a sufficient substrate level and synaptogenesis, because Ab is
released presynaptically, as mentioned above.
Some NSAIDs are known to preferentially lower Ab42 [33,34].
Our data showed that sulindac sulfide was capable of inhibiting
Ab42 secretion at high concentrations ($10
25 M) (Figure 6F),
although a few NSAIDs do not show therapeutic effects for AD.
Negative results might be due to low c-secretase modulator
potency [44]. To discover novel effective drugs for modulating b-
or c-secretase activity, the in vitro hiPS cell-derived neuronal cell
assay system might be expected to yield such drugs.
Familial AD patient specific neuronal cells generated by direct
conversion (induced neuron, iN) show higher Ab42/Ab40 ratio
than those of unaffected individuals [45]. Based on this report,
hiPS/hES cell-derived neurons expressing mutant PS1, PS2, or
APP may show higher Ab42/Ab40 ratio. Comparing to our
results, the levels of Abs in this assay (Ab40; ,1.7 ng/ml at day
52) is higher than that using iN cells (Ab40; ,0.1 ng/ml), although
iN cells become functional neurons more quickly. The optimiza-
tion of neuronal cell condition for comparison of the Ab42/Ab40
ratio between multiple iPS cell-derived neuronal cells may be
required.
In conclusion, our findings indicate that hiPS cell-derived
neuronal cells express functional b- and c-secretases related to the
production of Ab in the present experimental conditions. In
addition, our data provide the proof in principle that hiPS cell-
derived neuronal cells can be applied to drug screening and AD
patient-specific iPS cell research.
Materials and Methods
Antibodies and reagents
Primary antibodies used were as follows: mouse anti-Nestin
(1:200, Millipore, Temecula, CA), mouse anti-Tuj1 (1:2000,
Covance, Princeton, NJ), rabbit anti-GFAP (1:500, DAKO,
Carpinteria, CA), rabbit anti-Synapsin I (1:500, Millipore), mouse
anti-Cux1 (1:100, Abnova, Taipei, Taiwan), rabbit anti-Satb2
(1:1000, Abcam, Cambridge, UK), rat anti-Ctip2 (1:500, Abcam),
rabbit anti-Tbr1 (1:500, Abcam), rabbit anti-vGlut1 (1:1000,
Synaptic Systems, Go ¨ttingen, Germany), rabbit anti-Foxg1 (1:100,
Abcam), rabbit anti-GABA (1:1000, Sigma-Aldrich, St. Louis,
MO), rabbit anti-GAD65/67 (1:200, Millipore), mouse anti-PAG
[46] (1:500), rabbit anti-APP (1:15000, Sigma-Aldrich), mouse
anti-APP (1 mg/ml, Millipore), rabbit-anti BACE (1:2000, Merck,
Darmstadt, Germany) mouse anti-PS1 loop C-terminus (1:1000,
Millipore), rabbit anti-nicastrin (1 mg/ml, Thermo Scientific,
Rockford, IL), rabbit anti-Pen-2 (1:1000, Invitrogen, San Diego,
CA), mouse anti-MAP2 (1:200, Millipore), goat anti-ChAT (1:100,
Millipore), guinea pig anti-VAChT (1:500, Millipore), and mouse
anti-b-actin (1:15000, Sigma-Aldrich). We raised rabbit polyclonal
antibodies against the carboxyl terminals of human sAPPa
(hsAPPa) and sAPPb using the KLH-conjugated synthetic
peptides CRHDSGYEVHHQK and CKTEEISEVKM, respec-
tively (Figure S3). All animal experiments were performed in
compliance with the institutional guidelines at RIKEN Brain
Science Institute, and were approved by the Animal Care and Use
Committee (Permit number: H17-2B031). Each antibody was
purified with a peptide-conjugated column [47]. Alexa Fluor 488
and Alexa Fluor 594-conjugated secondary antibodies (Invitrogen)
were used for immunofluorescence.
The b-secretase inhibitor IV [31] and c-secretase inhibitor
XXI/Compound E [32] were purchased from Merck. Sulindac
sulfide (NSAID) was purchased from Sigma-Aldrich.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde in phosphate
buffered saline (PBS) for 30 min, and incubated in PBS
Figure 5. Ab was produced in hiPS cell-derived neuronal cells. (A) Ab40 or Ab42 secreted into the conditioned media and FL-APP were
measured by sandwich ELISA and western blot analysis, respectively. Expression level of Ab was normalized by that of FL-APP. (B) Ab42/Ab40 ratios.
Data represent the mean 6 SD of 8 assays.
*, #p,0.05,
**, ##p,0.01,
***, ###p,0.001, Tukey’s test.
doi:10.1371/journal.pone.0025788.g005
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inhibitor (GSI) (C, D), and NSAID (E, F) were added into hiPS cell-derived neuronal cell cultures at day 36 (dotted line) and 50 (bold line), and two days
later amounts of Ab40 and Ab42 secreted into the conditioned media were measured. The ratios Ab40/FL-APP and Ab42/FL-APP are expressed as
percentages of the vehicle-treated group at day 52 and represent mean 6 SD of 3 assays. A, B: There were significant main effects of day (F(1,
16)=72.5 and 162.4, p,0.001 in Ab40 and Ab42, respectively) and dose (F(3, 16) =23.1 and 45.7, p,0.001 in Ab40 and Ab42, respectively), and
significant interaction between day and dose (F(3, 16) =13.0 and 11.7, p,0.001 in Ab40 and Ab42, respectively) by 2-way ANOVA. C, D: There were
significant main effects of day (F(1, 28) =240.5 and 59.1, p,0.001 in Ab40 and Ab42, respectively) and dose (F(6, 28) =70.8 and 37.8, p,0.001 in
Ab40 and Ab42, respectively), and significant interaction between day and dose (F(6, 28) =23.5 and 15.1, p,0.001 in Ab40 and Ab42, respectively) by
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After blocking with 2% BSA in PBS, cells were incubated with
primary antibody diluted with blocking buffer and then washed
with PBS. Finally the cells were incubated with secondary
antibodies and mounted using ProLong Gold antifade reagent
with DAPI (Invitrogen). The immunoreactive cells were visual-
ized using an LSM 700 Laser Scanning Microscope (Carl Zeiss,
Jena, Germany) and a Biorevo BZ-9000 fluorescence microscope
(Keyence, Osaka, Japan).
Quantitative real-time RT-PCR
Total RNA was isolated from cells using TRIZOL reagent
(Invitrogen). Contaminating DNA was removed using the
TURBO DNA-free kit (Ambion, Austin, TX), and cDNA was
synthesized using ReverTra Ace-a (Toyobo, Osaka, Japan),
according to the manufacturers’ protocols. Real-time PCR was
performed using the StepOnePlus system (Applied Biosystems)
and SYBR green reagent (TAKARA, Shiga, Japan). The
primers used are listed in Table S2 in the supporting
information.
HiPS cell culture and differentiation into neuronal cells
HiPS cells, 253G4 [14] (passage 20–30) or hES cells, H9 were
cultured on mitomycin C-treated mouse embryonic fibroblasts in
primate ES medium (ReproCELL, Kanagawa, Japan) supplement-
ed with bFGF (Wako Pure Chemicals, Osaka, Japan). To obtain
cortical neurons derived from iPS cells, we partially modified a
previous method [12,15]. For neural induction, partially dissociated
iPS cell colonies, 40–100 mm in diameter, were selected with Cell
Strainer (BD Falcon, BD Bioscience, Bedford, MA) and plated on
poly-L-lysine (Sigma-Aldrich)/Laminin (BD Biosciences) (PLL/
LM)-coated dishes (P1) in N2B27 neuronal differentiation medium
[DMEM/F12 (Invitrogen), Neurobasal (Invitrogen), N2 (Invitro-
gen), B27 minus vitamin A (Invitrogen), L-Gln (Invitrogen)],
supplemented with 100 ng/ml human recombinant Noggin (R&D
Systems, Minneapolis, MN) and 1 mM SB431542 (Sigma-Aldrich)
for 17 days. At day 10, primary colonies were split into small clumps
using 200 U/ml collagenase with CaCl2 and plated into PLL/
Entactin-CollagenIV-Laminin(Millipore)(ECL)-coated dishes(P2).
At day 17, P2 cells were dissociated using Accutase (Innovative Cell
Technologies, San Diego, CA) and cultured on PLL/ECL-coated
dishes (P3). Finally, at day 24, cells dissociated with Accutase were
passed through a 40-mm cell strainer (BD Biosciences), counted,
and cultured on PLL/LM/Fibronectin (Millipore)-coated 24-well
plates at 2.5610
4 cells/well in N2B27 medium supplemented
with 10 ng/ml BDNF, GDNF, and NT-3 (R&D Systems).
Medium changes for cell culture were carried out once every
two or three days until day 52.
Ab sandwich ELISA
At days 38, 45, and 52, two-day incubated conditioned media
were collected from cultured neuronal cells and centrifuged at
4,000 g for 10 min. The resultant clear supernatants were
subjected to sandwich ELISA (Wako) with a combination of
monoclonal antibodies specific to the midportion of Ab and
specific to the C-terminal of Ab40 or Ab42, to determine the
amounts of secreted Ab, as described previously [20,28,30]. We
also examined the inhibitory effect of each drug on Ab production.
All media were replaced with new media containing each drug
and two-day conditioned media were analyzed as mentioned
above.
Western blot analysis
Western blot analysis was performed as previously described
with minor modification. In addition to conditioned media, cell
lysates were also collected, extensively washed with PBS, and lysed
2-way ANOVA. E, F: There were significant main effects of day (F(1, 20) =196.9 and 418.0, p,0.001 in Ab40 and Ab42, respectively) and dose (F(4, 20)
=4.16, p=0.013 and F(4, 20)=91.9, p,0.001 in Ab40 and Ab42, respectively), and significant interaction between day and dose (F(4, 20)=25.4,
p,0.001 in Ab42) by 2-way ANOVA.
*, #p,0.05,
**, ##p,0.01,
***, ###p,0.001, significantly different from respective vehicle-treated groups by
Dunnett’s test.
doi:10.1371/journal.pone.0025788.g006
Table 1. Panel of Ab monitoring systems.
Human sample Ab40 Ab42 Ref.
Brain tissue [AD] q(AD/NC) q(AD/NC) [39]
CSF [AD] -
R (AD/NC)
Q(AD/NC)
Q(AD/NC)
[37]
[29]
Plasma [AD] q(AD/NC) R (AD/NC) [29]
iPS cell-derived neuronal cells Measurable Measurable This report
Mouse model Ab40 Ab42 Ref.
Brain [PDAPP]
Brain [APP23]
Brain [Tg2576]
q(Aging)
q(Tg/non-Tg)
q(Aging)
q(Tg/non-Tg)
q(Aging)
q(Tg/non-Tg)
q(Aging)
q(Tg/non-Tg)
[36]
[27]
[28]
CSF [Tg2576] Q(Aging) Q(Aging) [28]
Plasma [Tg2576] Q(Aging) Q(Aging) [28]
Cell line Ab40 Ab42 Ref.
[APPNL-H4]
[CHO-APPNL/SH-SY5Y-APP]
Measurable
Measurable
Measurable
Measurable
[30]
[4]
AD, Alzheimer’s disease; NC, normal control; Tg, transgenic mouse model.
doi:10.1371/journal.pone.0025788.t001
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The media or cell lysates were separated by 5–20% gradient or
7.5% [FL-APP] or 10% [b-actin] sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to polyvinylidene difluoride membranes (Hybond-P; GE Health-
care, Buckinghamshire, UK). The blots were probed with an
appropriate primary antibody, followed by HRP-conjugated anti-
mouse or anti-rabbit IgG (GE Healthcare). The protein bands
were visualized using an enhanced chemiluminescence (ECL)
detection method (GE Healthcare), and band intensity was
analyzed with a densitometer (LAS-4000; GE Healthcare), using
the Science Laboratory 2001 Image Gauge software (Fujifilm,
Tokyo, Japan). Immunoreactive protein content in each sample
was calculated based on a standard curve constructed with each
recombinant protein or one of the samples. Each set of
experiments was repeated at least two times to confirm the results.
The level of b-actin protein, measured by quantitative western
blotting using b-actin antibody, was used as an extraction and
loading control.
LDH assay
Cell toxicity assays were performed using a cytotoxicity
detection kit (LDH, Roche, Mannheim, Germany) according to
the manufacturer’s protocol.
Statistical analysis
All data were expressed as mean 6 SD. Comparisons of mean
among more than three groups were done by one-way or two-way
ANOVA, followed by post-hoc test (PRISM, GraphPad software). P
values #0.05 indicated significant differences.
Supporting Information
Figure S1 Cholinergic neuronal marker-positive cells
were observed in hiPS cell-derived neuronal cells.
Expression levels of ChAT (A) and VAChT (B) were quantified
by qPCR (n=3) and normalized by that of GAPDH. ‘‘Fold
expression’’ represents the ratio of expression on the given day
compared to day 38. ChAT- (C) and VAChT (D)-positive cells
were observed a little at day 52.
(TIF)
Figure S2 Percentages of the three isoforms of APP
(APP770, APP751, and APP695) at 38, 45, and 52 days.
Each column represents mean 6 SD of 8 assays.
*p,0.05,
**p,0.01,
***p,0.001, Tukey’s test.
(TIF)
Figure S3 New hsAPPa and sAPPb antibodies specifi-
cally detect human sAPPa and sAPPb by western blots,
respectively. Human neuroglioma H4 cells overexpressing
wild-type APP (APPWT-H4 cells) were treated with a-secretase
activator (12-O-tetradecanoylphorbol 13-acetate (TPA)), a-secre-
tase inhibitor (TNF-a protease inhibitor-2 (TAPI-2)), or b-
secretase inhibitor (see Protocol S1). Brain lysates of APP-
knockout mice (APP-KO) were used as negative control.
Immunoblots of conditioned media and supernatants of brain
lysates were probed by anti-hsAPPa or anti-sAPPb antibody.
sAPPa or sAPPb derived from both exogenous APP695 and
endogenous APP770/751 are detected by each antibody. The
increase in sAPPa by a-secretase activator and the reduction in
sAPPa by a-secretase inhibitor effectively reached 434% and
50% of control (DMSO), respectively (upper panel). The decrease
in sAPPb by b-secretase inhibitor effectively reached 11% of
control (lower panel). Neither sAPPa nor sAPPb in the APP-KO
brain was detected by anti-hsAPPa or anti-sAPPb antibody,
respectively. An asterisk indicates a non-specific band.
(TIF)
Figure S4 Immunocytochemical characterization of
human ES cell (H9)-derived neuronal cells. (A) Time-
dependent morphological changes of cells reseeded in a 24-well
plate. Neuronal and glial cells were stained by anti-Tuj1 (left; red),
anti-synapsin I (left; green), anti-MAP2 (right; red), and anti-GFAP
(right; green) antibodies and DAPI (right; blue) at 38, 45, and 52
days. Scale bar, left; 20 mm, right; 50 mm. (B) ICC staining of
Tbr1-, Ctip2-, Cux1- and Satb2-positive cells at day 52. (C–E)
Neurotransmitter phenotypes at day 52. PAG (red)- and GAD
(green)-positive (C), Glut1 (green)- and Tuj1 (red)-positive (D), and
GABA (green)- and Tuj1 (red)-positive cells (E). Blue, DAPI. Scale
bar, 50 mm.
(TIF)
Figure S5 Ab production was modulated by several
drugs in human ES cell-derived neuronal cells. b-
Secretase inhibitor (BSI) (A, B), c-secretase inhibitor (GSI) (C,
D), and NSAID (E, F) were added into hES cell-derived neuronal
cell cultures at day 36 (dotted line) and 50 (bold line), and two days
later amounts of Ab40 and Ab42 secreted into the conditioned
media were measured. The ratios Ab40/FL-APP and Ab42/FL-
APP are expressed as percentages of the vehicle-treated group at
day 52 and represent mean 6 SD of 3 assays.
*, #p,0.05,
**, ##p,0.01,
***, ###p,0.001, significantly different from
respective vehicle-treated groups by Dunnett’s test.
(TIF)
Figure S6 Expression levels of reprogramming factors
of iPS cells in neural differentiation. Total and transgene
(Tg) expression levels of Sox2, Oct3/4 and Klf4 were measured by
qPCR. Bold and dotted lines represent total and transgene
expressions, respectively. ‘‘Fold expression’’ represents the ratio of
the expression level compared to the total expression level at day 0
(iPS cells).
(TIF)
Figure S7 Ab production was modulated by GSI in
human iPS cell (201B7)-derived neuronal cells. c-Secre-
tase inhibitor (GSI) was added into the hiPS cell line, 201B7-
derived neuronal cell cultures at day 36 (dotted line) and 50 (bold
line), and two days later amounts of Ab40 (A) and Ab42 (B)
secreted into the conditioned media were measured. The ratios
Ab40/FL-APP and Ab42/FL-APP are expressed as percentages
of the vehicle-treated group at day 52 and represent mean 6 SD
of 3 assays.
(TIF)
Protocol S1 Sampling method for checking antibody
specificity.
(PDF)
Table S1 Effects of secretion inhibitors on cell viability
measured by LDH assay at day 52.
(DOCX)
Table S2 qPCR primers.
(DOCX)
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